Physician profile
Shafi Raza
NPI 1811151160
$5,774.75
in general payments reported to CMS, 2019-2025
30 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $1,085 · 2021: $1,096 · 2022: $1,340 · 2023: $529 · 2024: $740 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,070.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $740.49 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $647.09 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $480.02 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $456.35 | 2020-2024 | Lokelma, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.00 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.78 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $202.16 | 2019-2024 | |
| Grifols USA, LLC | $194.14 | 2019-2022 | |
| Csl Behring | $179.02 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $177.93 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $165.39 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $138.03 | 2019-2022 | |
| Amgen INC. | $133.54 | 2019-2025 | Prolia, Evenity, Otezla |
| Abbvie INC. | $113.14 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $100.24 | 2023 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $76.91 | 2020-2024 | Eliquis |
| Allergan, INC. | $63.47 | 2019-2020 | |
| Amarin Pharma, INC. | $45.66 | 2020-2021 | |
| Exact Sciences Corporation | $37.34 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $36.59 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $33.16 | 2024 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $30.23 | 2024-2025 | Rexulti |
| Dexcom, INC. | $25.73 | 2024 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $23.58 | 2022 | |
| Abbott Laboratories | $23.42 | 2022 | |
| Melinta Therapeutics, LLC | $22.93 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.52 | 2022 | |
| Pfizer INC. | $18.29 | 2019 | |
| Djo, LLC | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shafi Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.